ArticleFrontiers in oncology2021
Diagnostic and Prognostic Potential of
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Radiomics for differentiating radiation-induced brain injury from recurrence in gliomas: systematic review, meta-analysis, and methodological quality evaluation using METRICS and RQS.European radiology · 2025Pooled it
- Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A Systematic Review and Meta-Analysis.AJNR. American journal of neuroradiology · 2025Pooled it
- Trial
- Review
- The diagnostic and prognosis value of dynamic contrast-enhanced MRI distributed parameter model andNeuroradiology · 2026Article
- Cutting-edge approaches in pet imaging for gliomas: current applications for neurooncologists and the path to theranostic breakthroughs.European journal of nuclear medicine and molecular imaging · 2026Review
- PET RANO 1.0 criteria improve prognostic stratification in high-grade gliomas usingJournal of neuro-oncology · 2026Article
- Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based onCancers · 2025Article
- Multidimensional in silico evaluation of fluorine-18 radiopharmaceuticals: integrating pharmacokinetics, ADMET, and clustering for diagnostic stratification.Journal of computer-aided molecular design · 2025Article
- Interobserver ground-truth variability limits performance of automated glioblastoma segmentation on [EJNMMI physics · 2025Article
- The role of FET-PET in patient selection and response assessment for reirradiation in recurrent glioblastoma.Frontiers in oncology · 2025Review
- Pre-operative dual-time-point [European journal of nuclear medicine and molecular imaging · 2025Article
- Comparison of PET/CT and PET/MRI in central nervous system tumors, a narrative review.International journal of physiology, pathophysiology and pharmacology · 2024Review
- Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [Journal of neuro-oncology · 2023Article
- Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer.Nature reviews. Clinical oncology · 2023Review
- Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Journal of neuro-oncology · 2023Review
- Imaging-Based Patterns of Failure following Re-Irradiation for Recurrent/Progressive High-Grade Glioma.Journal of personalized medicine · 2023Article
- In Vivo Quantitative Imaging of Glioma Heterogeneity Employing Positron Emission Tomography.Cancers · 2022Review
- Multi-threshold volumetricNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMRI-based differential diagnosis of glioma recurrence (GR) and treatment-induced changes (TICs) remain elusive in up to 30% of treated glioma patients. We aimed to determine
methodsWe retrospectively analyzed 45 glioma patients treated with chemoradiation therapy (32 males; mean age: 51 years, glioma grade: n=26 WHO4; n=15 WHO3; n=4 WHO2) who underwent
results
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.